Bovhyaluronidase azoximer

Lower urinary tract symptoms (LUTS) occur in 90% of middle-aged, elderly and senile men and are usually associated with benign prostatic hyperplasia (BPH). The prevalence of BPH and its negative impact on all aspects of a man's life force modern scientists to search for optimal and safe treatment strategies.

To evaluate the efficiency and safety of bovhyaluronidase azoximer (Longidaza, lyophilisate for injection and rectal suppositories 3,000 IU) in combination with the alpha-blocker tamsulosin in the treatment of patients with LUTS associated with BPH.

A total of 229 patients with LUTS associated with BPH were included in the study. They were randomly divided into an experimental group (n=118) and a control group (n=111). Patients in the experimental group received the drug Longidaza in 2 dosage forms together with tamsulosin, while in the control group, tamsulosin was administered as monotherapy. The evaluation was carried out in outpatient settings and included five timepoints. The duration of follow-up of patients throughout the study was no more than 138 days.

There were no differences between patients in the experimental and control groups in terms of baseline characteristics and duration of LUTS due to BPH (1.51+/-1.04 vs. 1.46+/-0.85 years, respectively). In the experimental group, there was a significantly more pronounced decrease in the level of symptoms according to the International Prostate Symptom Score (IPSS) at 60 (+/-1) and 130 (+/-3) days from the start of therapy compared to the baseline level (p = 0.031 and 0.004, respectively). Throughout the study, total prostate volume moderately decreased in all patients. According to the analysis of covariance, a significantly more pronounced decrease in the total NIH-CPSI score was also observed in the experimental group. In addition, in the main group the quality of life increased by 85.71%, while in the control group the positive dynamics was in 71.43% of cases. During laboratory examination it was found that the total PSA level remained virtually unchanged in patients of both groups, There were 5 adverse events (AE) in the experimental group and 14 in the control group, and none of the AE prevented the patients from continuing to participate in the study.

Our results indicate greater efficiency and safety of combination therapy with Longidaza and tamsulosin in patients with LUTS due to BPH compared to monotherapy with tamsulosin.

Idiopathic pulmonary fibrosis (IPF) is one of the most common forms of interstitial lung disease, characterized by progressive parenchymal fibrosis and respiratory failure. In a model of bleomycin-induced pulmonary fibrosis, the antifibrotic and anti-inflammatory activity of Longidaze (Bovhyaluronidase Azoxymer), which contains a conjugate of the hyaluronidase enzyme with a high molecular weight synthetic carrier azoxymer bromide, was investigated. Experiments were conducted in male C57BL/6 mice. Longidaze was administered at different doses by intranasal and intramuscular routes. Histology, hematology, and enzyme-linked immunosorbent assay were used in the study. The use of Longidaze reduced pulmonary fibrosis, as evidenced by an improvement in histopathologic damage to the lungs, a decrease in the area of connective tissue, and the levels of profibrotic factors (TGF-β1, hydroxyproline, collagen I) in lung tissue. In addition, Longidaze inhibited the inflammatory response in pulmonary fibrosis, and decreased the levels of IL-6, TNF-α, and hyaluronic acid in lung tissue and the recruitment of inflammatory cells into lung tissue. The highest therapeutic efficacy was observed with the use of Longidaze at doses of 120 and 1200 U/kg intramuscularly, which was superior to that of the reference drug pirfenidone axunio. The data presented in this study suggest that Longidaze is a new and promising drug for the treatment of IPF that warrants further investigation in patients with fibrotic interstitial lung disease.